Your browser doesn't support javascript.
loading
Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
Cui, Feilun; Qiu, Yue; Xu, Wei; Zou, Chen; Fan, Yu.
Afiliación
  • Cui F; Department of Urology, Affiliated Taizhou Second People's Hospital of Yangzhou University , 225500, Taizhou, China.
  • Qiu Y; Department of Urology, The Fourth Affiliated Hospital of Jiangsu University , 212002, Zhenjiang, China.
  • Xu W; Cancer Institute, The Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, 225500, Zhenjiang, Zhenjiang, China.
  • Zou C; Cancer Institute, The Affiliated People's Hospital, Jiangsu University, No. 8 Dianli Road, 225500, Zhenjiang, Zhenjiang, China.
  • Fan Y; Department of General Surgery, Suzhou Hospital, Affiliated Hospital of Medical School Nanjing University, No. 1 Lijiang Road, 215163, Suzhou, China. zouchenzhj@163.com.
BMC Cancer ; 24(1): 305, 2024 Mar 06.
Article en En | MEDLINE | ID: mdl-38448818
ABSTRACT

BACKGROUND:

A consensus has not been reached on the value of prostate-specific antigen density (PSAD) as a predictor of biochemical recurrence of prostate cancer. This meta-analysis aimed to evaluate the association between PSAD and biochemical recurrence of prostate cancer after primary treatment.

METHODS:

Two authors systematically searched PubMed, Web of Science, and Embase databases (up to August September 10, 2023) to identify studies that assessed the value of pretreatment PSAD in predicting biochemical recurrence after primary treatment (radical prostatectomy or radiotherapy) of prostate cancer. A random effect model was used to pool adjusted hazard ratios (HR) with 95% confidence intervals (CI) for biochemical recurrence.

RESULTS:

Nine studies with 4963 patients were eligible for the meta-analysis. The reported prevalence of biochemical recurrence ranged from 4 to 55.1%. For patients with higher PSAD compared to those with low PSAD, the pooled HR of biochemical recurrence was 1.59 (95% CI 1.21-2.10). Subgroup analysis showed that the pooled HR of biochemical recurrence was 1.80 (95% CI 1.34-2.42) for patients who received radical prostatectomy, and 0.98 (95% CI 0.66-1.45) for patients who received radiotherapy.

CONCLUSIONS:

Elevated pretreatment PSAD may be an independent predictor for biochemical recurrence of prostate cancer after radical prostatectomy. Determining PSAD could potentially improve the prediction of biochemical recurrence in patients with prostate cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Límite: Humans / Male Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Límite: Humans / Male Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China